Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0E3JL
|
||||
Former ID |
DIB011036
|
||||
Drug Name |
SL-25.1188
|
||||
Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Discontinued in Phase 1 | [1] | ||
Company |
Sanofi-Synthelabo
|
||||
Target and Pathway | |||||
Target(s) | Amine oxidase [flavin-containing] B | Target Info | Inhibitor | [2] | |
BioCyc Pathway | Superpathway of tryptophan utilization | ||||
Tryptophan degradation via tryptamine | |||||
Dopamine degradation | |||||
Putrescine degradation III | |||||
Noradrenaline and adrenaline degradation | |||||
KEGG Pathway | Glycine, serine and threonine metabolism | ||||
Arginine and proline metabolism | |||||
Histidine metabolism | |||||
Tyrosine metabolism | |||||
Phenylalanine metabolism | |||||
Tryptophan metabolism | |||||
Drug metabolism - cytochrome P450 | |||||
Metabolic pathways | |||||
Serotonergic synapse | |||||
Dopaminergic synapse | |||||
Cocaine addiction | |||||
Amphetamine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
5-Hydroxytryptamine degredation | |||||
Dopamine receptor mediated signaling pathway | |||||
Pathway Interaction Database | Alpha-synuclein signaling | ||||
WikiPathways | Tryptophan metabolism | ||||
Dopamine metabolism | |||||
Phase 1 - Functionalization of compounds | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012921) | ||||
REF 2 | [(11)C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate. Synapse. 2010 Jan;64(1):61-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.